Melanoma biomolecules: independently identified but functionally intertwined

Area of Science:

• Oncology
• Molecular Biology
• Dermatology

Background:

• Early-stage melanoma (<1mm) has a good prognosis, but 5% of patients experience recurrence and mortality within 10 years.
• Current prognostic markers for melanoma are often insufficient when used individually.
• Identifying patients at high risk for recurrent melanoma necessitates novel prognostic markers.

Purpose of the Study:

• To review the roles of five key biomarkers in melanoma biology and metastasis.
• To explore the potential of a combination of interacting proteins as prognostic markers for melanoma.
• To provide context on melanoma cell adhesion molecule (MCAM), galectin-3 (gal-3), matrix metalloproteinase 2 (MMP-2), chondroitin sulfate proteoglycan 4 (CSPG4), and paired box 3 (PAX3).

Main Methods:

• Literature review and meta-analysis of studies on gene and protein expression in melanoma.
• Analysis of individual and combined roles of five putative biomarkers in melanoma metastasis.
• Focus on proteins regulating different aspects of the metastatic pathway.

Main Results:

• Each of the five biomarkers (MCAM, galectin-3, MMP-2, CSPG4, PAX3) has been independently identified as a potential prognostic marker.
• These biomarkers are interconnected and play intertwined roles in melanoma biology and metastasis.
• A combination of interacting proteins involved in multiple metastatic stages may offer improved prognostic value.

Conclusions:

• Individual biomarkers have limited prognostic value in melanoma.
• Analyzing a panel of interacting biomarkers offers a promising approach for identifying high-risk melanoma patients.
• Further research into the combined roles of MCAM, galectin-3, MMP-2, CSPG4, and PAX3 is warranted for improved melanoma prognostication.